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Rev7™ is an indigestible gum polymer used for the manufacturing of chewing gum. It allows for the for-
mulation of chewing gum with low adhesion; thus can be readily removed from surfaces such as side-
walks, clothing, carpets and furniture. In a toxicological safety assessment, Rev7™ was found to be
non-mutagenic in the AMES assay. The highest concentration tested in a mouse lymphoma thymidine
kinase locus gene mutation assay induced a slight but biologically relevant increase in mutations under
non-metabolic activation conditions after 24 h. Because of this ﬁnding, a mouse micronucleus assay was
performed, and the test article was found to be negative for inducing chromosomal damage. A 28-day
repeated oral toxicity study resulted in a NOAEL of 80,000 ppm; the highest concentration tested. Rev7™
was found to be free from contaminants such as heavy metals, monomers, and solvents. Lastly, Rev7™
did not demonstrate skin-sensitizing properties in the murine local lymph node assay.
 2009 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
The challenges of discarded chewing gum in the environment
and the economic costs of cleaning up this litter have become seri-
ous issues; so much so that there are companies that now special-
ize in chewing gum removal (Milov et al., 1998; Strugatch, 2002).
Rev7™ was speciﬁcally developed to aid in solving problems asso-
ciated with discarded chewing gum, by being non-adhesive to sur-
faces often littered with gum.
Chewing gum is typically manufactured using an insoluble gum
base blended with soluble sweeteners and ﬂavorings. Chewing, butylated hydroxytoluene;
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-NC-ND license. gum bases may be made of a single ingredient, or of a blend of
ingredients, such as elastomers, resins, emulsiﬁers, waxes and ﬁll-
ers (Imfeld, 1999). The gum base typically comprises less than 50%
of the ﬁnal chewing gum product (Imfeld, 1999).
Gum bases typically utilize synthetic polymer elastomers to
give them the necessary consistency and mastication properties
desired for these products. While the elastomers used in gum bases
have the necessary mechanical properties that make them ideal for
chewing, these compounds are hydrophobic and highly adhesive to
surfaces that contain hydrophobic components. Natural elastomers
such as latex or vegetable sources such as chicle, which is com-
posed of cis- and trans-polyisoprene (Rose and Steinbuchel, 2005)
were predominantly used in the past. However, synthetic elasto-
mers are more commonly used today in their place (Milov et al.,
1998).
Rev7™ is a synthetic polymer that contains a maleic anhydride-
grafted cis-polyisoprene backbone (Fig. 1). It additionally contains
a hydrophilic component made of methoxypolyethylene glycol
(MPEG), a commercially available polyethylene glycol with one of
the two terminal hydroxyl groups capped by a methyl ether group.
The addition of this hydrophilic component results in decreased
adhesive properties to surfaces such as sidewalks, clothing, car-
pets, and furniture, and allows for the use of water to aid in the re-
moval of the gum base from these surfaces.
To establish a safety proﬁle for this novel synthetic polymer,
Rev7™ was screened for a battery of compounds that could theo-
retically contaminate the product during the manufacturing pro-
Fig. 1. A representation of the reaction between the components PIP-g-MA and MPEG to produce Rev-7™, where m = 366–1248, n = 3–15 and p = 44–50.
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other potential by-products. In addition to this screening, several
genetic and oral toxicology tests were performed, including the
bacterial reverse mutation assay (AMES), the mouse lymphoma
thymidine kinase gene mutation assay, the mammalian erythro-
cyte micronucleus test, and a 28-day repeated oral toxicity study
in rats. Finally, in order to determine the possible risk of Rev7™
to cause skin sensitization reactions, a murine local lymph node as-
say was performed on the ingredient.
2. Materials and methods
2.1. Test article
The proprietary polymer and test article, Rev7™, is manufactured for Revoly-
mer, Ltd. (Flintshire, United Kingdom). The backbone of Rev7™, referred to as
PIP-g-MA, is made of cis-polyisoprene (PIP) with approximately three moles of
maleic anhydride-grafted per polymer chain. PIP-g-MA is manufactured in a plant
used to produce polymers for many applications. The manufacturer produces a con-
taminant-free product by ensuring only pure polyisoprene is produced immediately
prior to PIP-g-MA, performing a hexane wash between grades, not supplying theﬁrst batch following changeover, and thorough testing of the ﬁnal product to con-
ﬁrm that it meets speciﬁcations. Rev7™ is manufactured by reacting PIP-g-MA with
methoxypolyethylene glycol (MPEG – pharmaceutical grade) using heat. The ﬁn-
ished product is referred to as a comb polymer, because the MPEG chains hang from
the PIP-g-MA backbone in a similar arrangement to the teeth found on a comb. The
MPEG becomes chemically attached to the PIP-g-MA through the opening of the
anhydride ring present on the PIP-g-MA molecule. The disappearance of the anhy-
dride group is monitored using Fourier Transformation Infra Red (FT-IR). If neces-
sary, excess anhydride is removed by water hydrolysis after the reaction is
complete. The speciﬁcation for anhydride concentration in Rev7™ is 15 lmol/g.
The ﬁnal product contains approximately 70% by weight of Rev7™, and 30% by
weight of free and unbound methoxypolyethylene glycol (MPEG).2.2. Chemical analyses of Rev7™
Chemical analyses were performed on Rev7™ to identify potential contami-
nants from raw materials, solvents, stabilizers, catalysts, neutralizing agents, or
by-products from manufacturing. Screened compounds included heavy metals,
monomeric and solvent residues, as well as butylated hydroxytoluene (BHT). These
analyses were completed by specialized laboratories with expertise in the analysis
of polymeric samples. All methods were validated by the addition of standards or
use of a calibration curve where possible.
T.M. Farber et al. / Food and Chemical Toxicology 48 (2010) 831–838 8332.2.1. Heavy metals analysis
Rev7™ was tested for antimony, arsenic, cadmium, lead, mercury aluminum,
chromium, copper, lithium and zinc. The study was conducted at Reading Scientiﬁc
Laboratories Limited (The Lord Zuckerman Research Centre, UK), using methods
based on the European Pharmacopoeia (Ph Eur) Section 2.2.23, with a modiﬁcation
of using inductively coupled plasma mass spectroscopy (ICP-MS) to reach lower
detection limits.
A ﬁxed volume of concentrated nitric acid was added to the test article, and it
was digested using a microwave oven. Internal standards of rhodium and gold were
added, and the sample was brought up to volume using puriﬁed water. A series of at
least four standards per heavy metal were prepared in solutions containing dilute
nitric acid, rhodium and gold, and were used to plot the calibration curves for each
of the heavy metals analyzed. Triplicate injections were made for each sample of
Rev7™, and results were averaged. The following ions were used for quantiﬁcation
of each element: Cadmium 111; lead 208; antimony 121 and 123; arsenic 75; alu-
minum 27; chromium 52; copper 63; lithium 7 and zinc 64. For mercury analyses,
concentrated hydrochloric acid and a solution of tin (II) chloride in dilute hydro-
chloric acid were added to the samples.
2.2.2. Monomer and solvent residue analysis
Monomer residue analyses were performed at Intertek Testing Services (Wirral
and Manchester, UK). The methods utilized followed the European Pharmacopeia
guidelines, including: Section 2.2.28 for isoprene analysis (GC/MS), Section 2.2.30
for maleic anhydride analysis (gel permeation/size exclusion chromatography), Sec-
tion 2.4.25 for ethylene oxide analysis (GC/MS), and Section 2.4.24 for hexane and
methanol analyses (GC/MS and GC/FID, respectively).
2.2.3. Butylated hydroxytoluene (BHT) analysis
Approximately 1 g of Rev7™ was dissolved in 10 mL of chloroform. A series of
BHT standards were prepared ranging from 20 ppm to 80 ppm. Multiple injections
of the sample solution were compared to the BHT standards using GC/MS (Agilent
Technologies 5890/5975). Selected ion monitoring was used to detect ions at 205
and 220. Both were used for quantiﬁcation.
2.3. Toxicology testing
2.3.1. Bacterial reverse mutation assay (AMES test)
Rev7™ was assayed via the Ames test according to OECD Guideline 471 (1997);
UKEM Guidelines (1990); and ICH Harmonised Tripartite Guideline, (1995 and
1997) for gene mutation capability in ﬁve histidine-requiring strains of Salmonella
typhimurium (TA98, TA100, TA1535, TA1537 and TA102) obtained from the UK Na-
tional Collection of Type Cultures (with the exception of strain TA102, which was
obtained from Glaxo Group Research Limited). The strains were tested both in
the absence and in the presence of metabolic activation by an Aroclor 1254 induced
rat liver post-mitochondrial fraction (MolTox™ S-9, obtained from Molecular Tox-
icology Incorporated, Boone, NC, USA), in two separate experiments. All treatments
were performed with Rev7™ formulated in tetrahydrofuran (THF).
Final plate concentrations of the positive controls in tests without metabolic
activation were 5.0 lg 2-nitroﬂuorene (strain TA98), 2.0 lg sodium azide (strains
TA100 and TA1535), 50.0 lg 9-aminoacridine (strain TA1537), and 0.2 lg mitomy-
cin C (strain TA102). Final plate concentrations of positive controls for tests with
metabolic activation were 10.0 lg benzo[a]pyrene (strain TA98), 5.0 lg 2-aminoan-
thracene (strains TA100, TA1535 and TA1537), and 20.0 lg 2-aminoanthracene
(strain TA102). The negative control was the vehicle (THF).
Test concentrations for the dose range-ﬁnding experiment and Experiment 1
were 1.6, 8, 40, 200, 1000 and 5000 lg/plate. Test concentrations for Experiment
2 were narrowed to 51.2, 128, 320, 800, 2000 and 5000 lg/plate for all strain
treatments.
2.3.2. Mouse lymphoma thymidine kinase gene mutation assay
Rev7™ was analyzed in the mouse lymphoma TK gene mutation assay accord-
ing to OECD Guidelines for Testing of Chemicals, No. 476 (1997), EEC Directive
2000/32 L 136 Annex 4E B 17 (2000), EPA Health Effects Test Guidelines, OPPTS
870.5300 (1998), and ISO 10993-1 (2003), -3 (2003, -12 (2007).
Mouse Lymphoma L5178Y cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). The test article was extracted in RPMI + 3% HS med-
ium at a weight/volume ratio of 0.2 g/mL according to guidelines. This extract cor-
responds to the highest concentration evaluated (100%). The negative control
consisted of the extraction medium alone. The positive controls for the samples that
did not undergo metabolic activation were 200 lg/mL and 500 lg/mL ethylme-
thanesulfonate (EMS), and 10 lg/mL methylmethanesulfonate (MMS) (both from
Sigma–Aldrich, Poole, UK). The positive control for the samples that underwent
metabolic activation was 3.5 lg/mL benzo[a]pyrene (B[a]P) (Fluka Chemical Corp.,
Milwaukee, WI, USA). The S9 liver microsomal fraction used for metabolic activa-
tion was prepared at BSL Bioservice (Planegg, Germany).
In Experiment 1, Rev7™ was assayed in both the presence and absence of met-
abolic activation using a 4-h exposure period at concentrations of 8.6, 25.9, 43.2,
51.8, 60.5, 69.1, 77.7, and 86.4% of the extracted material. In Experiment 2, the test
article was assayed with metabolic activation, at concentrations of 10, 25, 40, 55,70, 82.5, 92.5 and 100% of the extract for a 4-h exposure period. During testing
without metabolic activation, the exposure period was extended to 24-h, using test
article concentrations of 15, 40, 50, 60, 70, 80, 90 and 95% of the extract.
2.3.3. Mammalian erythrocyte micronucleus test
The study followed the guidelines set forth by OECD Guidelines No. 474 (1997),
EEC Directive 2000/32 L 136, Annex 4C B 12 (2000), EPA Health Effects Test Guide-
lines OPPTS 870.5395 (1998), ISO 10993-1,(2003) -3,(2003), -12(2007).
Male and female mice of strain NMRI, aged 7–12 weeks were obtained from
Harlan Winkelmann (Borchen, Germany). Animals were housed ﬁve per cage at a
temperature of 19–25 C, humidity of 55 ± 10%, and a 12 h light–dark schedule.
They were fed Altromin 1324 maintenance diet for rats and mice TPF, and given
tap water ad libitum.
The test item was extracted in physiologic saline – 0.9% NaCl (polar) and Cot-
tonseed Oil (non-polar) with a mass/volume ratio of 0.2 g/mL according to ISO
guidelines. Cyclophosphamide (Sigma–Aldrich, Poole, UK) served as the positive
control, and was administered intraperitoneally at a concentration of 40 mg/kg.
The doses were: 100% extract concentration, 50%, and 20% (corresponding to 1,
0.5 and 0.2 maximum tolerated dose (MTD), respectively). The animals received
the test item extracts once by intraperitoneal injection.
2.3.4. 28-Day toxicity study in the rodent
The study was conducted in accordance with OECD Guideline for Testing of
Chemicals, No. 407 (1997): Health Effects (1995) and US FDA Redbook 2000, IV.C.3a
Short-Term Toxicity Studies with Rodents (2003).
A group of 104 Hsd: Sprague Dawley SD rats aged 6–7 weeks were obtained
from Harlan Laboratories (Indianapolis, IN). The rats were housed singly in stainless
steel cages in a room controlled for temperature (17–21 C) and humidity (36–65%)
and a 12-h light/dark cycle. The animals were acclimated to the housing facility for
6 days prior to testing. Eighty healthy rats were chosen based on weight speciﬁca-
tions and health state, and were randomized into four groups of 20 rats (10/sex/
group). The rats were fed a diet of PMI LabDiet Certiﬁed Rodent Meal #5002, con-
taining 0 ppm (Group 1) and approximately 30,000 ppm (Group 2), 50,000 ppm
(Group 3) or 80,000 ppm (Group 4) of the test substance. The predicted human
exposure level of Rev7™ was determined to be 0.78 g/day prior to initiation of
the study. Information from Wrigley’s, the leading manufacturer of chewing gum
based products, concerning the consumption of chewing gum, reports that the aver-
age person in the US consumes 170–180 servings of chewing gum per year. At a
typical weight of 2.9 g per stick (Wrigley’s spearmint gum), this results in a ﬁgure
of 1.43 g/day. However, a recent report from Leatherhead Food International indi-
cates that US consumers chew 0.63 kg of gum per year, resulting in a ﬁgure of
1.72 g/day (Anon, 2005). For the purpose of the calculations, the higher value of
1.72 g/day will be used. On the basis of guidelines issued by JEFCA for evaluating
food intake, the daily consumption for heavy consumers of chewing gum can be
extrapolated by multiplying the average consumption by a factor of 3 (FAO/WHO,
1989). This results in a heavy user consuming 5.16 g chewing gum per day. Using
this ﬁgure as a guide for the maximum exposure of Rev7™ and since Rev7™ will
typically constitute a maximum of 15% by weight of any chewing gum formula,
the resulting maximum exposure is calculated to be 0.78 g of Rev7™ per day.
Concentrations for the study were then selected to result in 156, 260 and 416
times the expected human exposure, based on daily rat consumption of 20 g/
350 g rat/day. All diets were prepared once weekly and refrigerated until used.
The test and control diets were given to the respective groups on day 0 of the
study. Additional feed was provided as needed throughout the study to ensure ad
libitum feeding. Each prepared diet (all concentrations) was sampled on speciﬁed
days stated below, and frozen until analyzed. The diets were chemically analyzed
for stability (sampled on days 4, 7 and 10), homogeneity (sampled prior to con-
sumption from top, middle and bottom levels of the diet mixer) and concentration
veriﬁcation (sampled on days 4, 14 and 21) of the test substance.
The animals were observed twice daily for mortality, and daily for signs of gross
toxicity and behavioral changes. Detailed clinical observations were recorded both
while handling the animals and with the animals placed in an open ﬁeld on day 0
and weekly thereafter. Body weights were recorded twice during the acclimation
period and weekly thereafter. Individual food consumption was recorded weekly
to coincide with body weight measurements.
A Functional Observational Battery (FOB) (Moser, 1991) was performed at the
end of the fourth week of the study. The animals were observed in random order,
without the observer having knowledge of the group each animal belonged to. Each
animal was evaluated during handling and while in an open ﬁeld for excitability,
autonomic function, gait, sensorimotor coordination, reactivity, and sensitivity as
well as any other abnormal clinical signs.
At the end of the fourth week, a motor activity (MAct) test was performed;
where forelimb and hindlimb grip strength as well as foot splay measurements
were obtained in triplicate for all study animals. Blood was sampled from all ani-
mals on day 29 for hematology and clinical chemistry analysis and on days 31–
32 prior to necroscopy for coagulation assessments. The day before collection of
the blood samples for clinical pathology evaluation, the animals were fasted and ur-
ine samples were collected from each animal. Serologic assessments were also per-
formed on blood samples from two randomly chosen animals. Gross pathological
examinations were performed on all rats in the study. Tissue samples were col-
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and females on day 32). Selected organs, tissues, and any observed lesions from
the control and highest (80,000 ppm) dietary level groups (10 per Group) were for-
warded for histolopathological evaluation and reporting by a board-certiﬁed
pathologist.
2.3.5. Murine local lymph node assay
The study was conducted in compliance with Method B42 of Commission Direc-
tive 2004/73/EC, OECD Guidelines for Testing of Chemicals, Method No. 429 (2002)
and EPA OPPTS 870.2600 (2003).
Nulliparous, non-pregnant female CBA/CaOlaHsd strain mice were obtained
from Harlan UK Limited (Bicester, UK). After an acclimatization period, overtly
healthy animals with body weights of 17–21 g were arbitrarily allocated to the
study groups. The mice were approximately 10–11 weeks old at the commence-
ment of the study. The animals were maintained in a room with a temperature
range of 19–25 C, a humidity range of 40–70%, a 12-h light–dark schedule with
15 air changes per hour, and with water ad libitum and SQC (E) Rat and Mouse
Maintenance Diet No. 1 from Special Diets Services Ltd. (Witham, UK).
The test article vehicle and positive control for the study were supplied by Sig-
ma–Aldrich Co. Ltd. (Poole, UK), and consisted of dimethylformamide and a-hexyl-
cinnamaldehyde (25% in acetone/olive oil in a ratio of 4:1 v/v), respectively.
Tritiated 3H-methyl thymidine (3HTdR) was obtained from GE Healthcare UK Lim-
ited (Little Chalfont, UK), and was diluted in phosphate buffered saline to a ﬁnal
concentration of 80 lCi/mL.
3. Results
3.1. Chemical analysis of Rev7™
Speciﬁcations determined by Revolymer for Rev7™ include the
following: total heavy metals (<5 mg/kg), aluminum (<3 mg/kg),
lithium (<0.5 mg/kg), isoprene (<0.05 mg/kg), ethylene oxide
(<1 mg/kg), maleic anhydride (<0.2%), hexane (<0.75 mg/kg), meth-
anol (<2 mg/kg) and BHT (<750 mg/kg). Three independent batches
of Rev7™ were analyzed for each chemical, and all met the stated
speciﬁcations. Arsenic, cadmium, lead, and mercury were present
at concentrations of less than 0.05, 0.5, 0.005 and 0.03 mg/kg,
respectively; these levels are well within those considered safe
based upon a 2 g serving per day of Rev7™ (which is greater than
the expected daily consumption) (McGufﬁn, 2008; California Ofﬁce
of Environmental Health Hazard Assessment, 2009). Chromium,
copper and zinc were present at average levels of 0.76, 0.16, and
0.6 mg/kg, respectively. Based upon a 2 g serving, exposure to
these minerals is only a small fraction of established dietary refer-
ence intakes (Food and Nutrition Board, 2004).
3.2. Toxicology testing
3.2.1. AMES bacterial reverse mutation assay
The AMES assay was performed to assess the mutagenic poten-
tial of Rev7™ in ﬁve Salmonella typhimurium strains. No evidence of
toxicity was noted in the initial range-ﬁnding study, Experiment 1
(without pre-incubation) or Experiment 2 (with pre-incubation).
Precipitation of the test article was observed at P2000 lg/plate
in all Experiment 2 pre-incubation mixes in the presence of S9,
as well as on most test plates following the incubation period,
and in some strains at 800 lg/plate.
The test article demonstrated no evidence of mutagenicity in
this assay. The mean numbers of revertant colonies on negative
control plates were all considered within acceptable levels, and
the number of revertants was signiﬁcantly elevated by the positive
control treatments.
3.2.2. Mouse lymphoma TK gene mutation assay
This study was performed to assess the potential of Rev7™ to
induce mutations at the mouse lymphoma TK locus. In Experiment
1 the relative total growth of the L5178Y cells after treatment with
the highest concentration tested (86.4% extract) was 95.49% and
64.93%, for cells with and without metabolic activation, respec-
tively. This was compared to positive control values of 72.08%(B[a]P-with metabolic activation), 68.94% and 86.95% (EMS and
MMS: without metabolic activation). The mutation factor for the
highest dose group with metabolic activation was 0.66, as com-
pared to 3.11 for the positive control. The mutation factor was
1.55 in the group without metabolic activation, as compared to
12.68 and 4.42 for the positive controls.
In Experiment 2 with metabolic activation, the relative total
growth after treatment was 85.88% for the highest concentration
evaluated (100%). Treatment without metabolic activation resulted
in a relative total growth of 10.38% at the highest concentration
tested (95%). The growth inhibition by Rev7™ without metabolic
activation in both experiments was considered biologically
relevant.
Additionally, treatment with Rev7™ without metabolic activa-
tion induced a biologically relevant increase in the number of mu-
tants in Experiment 2, only in the highest concentration evaluated
(95%). The mutation factor for this concentration was 2.43, which
was slightly above the historical control data and exceeded the
threshold value of 2. In comparison, the positive controls EMS
and MMS showed mutation factors of 15.92 and 14.81, respec-
tively. Moreover, a mutation factor dose–response relationship
was observed for the test article in Experiment 2 without meta-
bolic activation, although only the highest concentration was bio-
logically relevant. With metabolic activation, no biologically
relevant increase in the number of mutants was found after treat-
ment with Rev7™.
Lastly, in Experiment 2 without metabolic activation, colony
sizing indicated potential clastogenic effects induced by the test
article under the experimental conditions. The quotient of large
to small colonies for concentrations 80, 90 and 95% were 2.00,
0.68 and 0.72, respectively. This is in comparison to negative con-
trol values of 5.18 and 4.08, and a positive control (MMS) value of
0.54. In the experiments with metabolic activation, colony sizing
did not indicate any potential for clastogenic effects/chromosomal
aberrations induced by Rev7™.
The positive controls EMS, MMS, and B[a]P showed distinct and
biologically relevant increases in mutation frequency. Additionally,
MMS and B[a]P signiﬁcantly increased the number of small
colonies.
Under the experimental conditions reported, Rev7™ is consid-
ered to be mutagenic in the mouse lymphoma TK locus assay using
the cell line L5178Y.
3.2.3. Mammalian erythrocyte micronucleus test
This genotoxicity study was performed to investigate the poten-
tial of Rev7™ to induce micronuclei formation in polychromatic
erythrocytes in the bone marrow of the mouse. The positive con-
trol (cyclophosphamide) induced a signiﬁcant increase in micronu-
clei formation frequency. The negative control data was within the
range of historical control data.
The animals treated with polar solvent extractions of the test
article showed no signs of systemic toxicity at any of the dose lev-
els tested. All animals treated with the middle and highest dose
levels of the non-polar solvent extractions demonstrated signs
such as: reduction of spontaneous activity, rough fur, cramps,
prone position and constricted opisthosoma. These signs were ob-
served at 4 h after treatment, but were not present at 44 or 68 h.
No biologically relevant increase in micronuclei formation was
found after treatment with the test item extracts in any of the dose
groups evaluated. The mean values noted for the treatment groups
were within the negative control data range and/or within the
range of the historical control data. No statistically signiﬁcant
enhancement (p < 0.05) of cells with micronuclei was noted in
the test item concentrations, except for the 0.5 MTD (44 h) female
group treated with the polar solvent extraction (p < 0.02), the 1.0
MTD (68 h) male group treated with the polar solvent extraction
Table 1
Mean daily intake of Rev7™ in 28-day repeated dose oral toxicity study in Sprague
Dawley rats.
Group number Feed
concentration
of Rev7™
(ppm)
Targeted
intake
(mg/kg/day)
Actual intake
males
(mg/kg/day)
Actual intake
females
(mg/kg/day)
1 0 0 0 0
2 30,000 1714 2394 2352
3 50,000 2857 4160 4182
4 80,000 4571 6879 6844
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with the non-polar solvent extraction (p < 0.02). Taken as a whole,
the observed non-patterned signiﬁcant ﬁndings in some of the
groups were regarded as not biologically relevant. Thus Rev7™ is
not considered genotoxic in the mouse micronucleus test.3.2.4. 28-Day repeated oral toxicity study in rats
A 28-day repeated dose oral toxicity study was conducted in
Hsd: Sprague Dawley rats to determine the potential toxic effects
of continuous exposure to Rev7™. The test article was considered
stable over the course of the study as determined by gel perme-
ation chromatography. Homogeneity studies found a maximum
of 4000 ppm variation between the top, middle and bottom levels
of the dietary mix; measured values ranged from 28 to 32,000 ppm
for group two, 49–52,000 for group three, and 77–81,000 for group
four. Concentration veriﬁcation studies showed an average recov-
ery consistent with theoretical values for the test article; namely
28,500 ppm, 51,000 ppm and 79,500 ppm for the respective groups
2–4. The stability of Rev7™ in the 30,000 ppm diet mix remained
greater than 92% of theoretical concentration on the study days
tested. Stability samples for 50,000 and 80,000 ppm resulted in
85% and 84% of the theoretical yield, respectively. Despite the
slight variability at the higher dose levels, Rev7™ was considered
stable in the dietary mix over the course of the 10-day determina-
tion. The mean daily intake of Rev7™ by the rats (days 0–28) is
shown in Table 1.
There were no changes in mortality, body weight, body weight
gain, food consumption, food efﬁciency or FOB/MAct ﬁndings re-
lated to test substance exposure in any of the rats, as is shown in
Table 2. A reduction in overall food efﬁciency was noted in group
2 males during weeks 1 and 3, in group 4 males during week 3,
and in group 2 females during week 2. These ﬁndings were consid-
ered incidental and non-adverse because body weight gain
changes were not correlated with food consumption or food efﬁ-
ciency changes over the course of the 4-week study.
FOB ﬁndings included a curled up sleeping posture (males: 2 in
group 1, 1 in group 4, females: 1 in group 1) and no tactile response
on manipulative testing (male: 2 in group 1, 3 in groups 2 and 3,
and 4 in group 4, females: 1 in group 1, 3 in group 2, 4 in group
3). The incidence of these ﬁndings was comparable for both the
control and treatment groups, and was not associated with a con-
stellation of ﬁndings that would support any toxicologically signif-
icant behavioral change. There were no signiﬁcant differences
observed in motor activity between the test and control groups.
There were no signiﬁcant changes in the coagulation or urinal-
ysis parameters tested (data not shown). While there were several
statistically signiﬁcant changes in the hematology and clinical
chemistry parameters (see Table 2), none were considered of tox-
icological or clinical signiﬁcance. They were either unrelated to
dose and the magnitude of the change was not clinically signiﬁ-
cant, and/or they were not accompanied by any other correspond-
ing clinical or histopathological changes.There were no macroscopic or microscopic changes in any test
animal that were considered related to treatment with Rev7™.
Incidental ﬁndings included two males in group 2 and three males
in group 4 that exhibited transient red ocular discharge between
study days 21–23 (but were normal at the end of the study), one
group 3 male with a diaphragmatic hernia and congestion of the li-
ver (conﬁrmed histologically), and another group 3 male that dis-
played small-appearing testes conﬁrmed to have moderate, diffuse,
bilateral tubular atrophy. A signiﬁcant reduction in mean absolute
testes weight observed in group 3 males was due to this single ani-
mal. In addition, one group 3 female exhibited a small-appearing
heart, and several females had the common and often estrous-re-
lated ﬁnding of ﬂuid-ﬁlled uteri and fallopian tubes, noted in two
control females, four group 2 females, and one group 4 female,
all without histological correlations. A mild increase in inﬂamma-
tion and/or hemorrhaging in the Harderian gland in both sexes of
group 4 were considered not toxicologically active, as they are
commonly associated with slight trauma after blood collection
from the retro-orbital sinus. Signiﬁcant reductions in the mean li-
ver weight in group 3 females and reductions in the spleen-to-
brain weight ratio observed in the group 2 females without clinical
or histopathologic change were also considered incidental.
3.2.5. Murine local lymph node assay
The murine local lymph node assay was performed to deter-
mine the potential of Rev7™ to cause allergic contact dermatitis.
All animals survived the treatment with Rev7™. There were no
clinical signs or body weight changes observed that would suggest
a systemic effect from the treatment. The SI values for the test arti-
cle concentrations were 1.44 for the 10% group, 1.98 for the 25%
group and 1.09 for the 50% group. The positive control value was
12.15. Because the test article values were below 3.0, Rev7™ does
not meet the criteria for classiﬁcation as a sensitizer. Thus, Rev7™
possesses no skin sensitization properties under the conditions of
this assay.4. Discussion
Chewing gum is a multibillion-dollar industry, and Americans
may consume as much as 2.5 kg of gum per capita annually (Ly
et al., 2008). This corresponds to approximately 6.9 g per person
per day, or a little over 3.5 average sticks of gum per day. The novel
polymer Rev7™ offers an alternative gum base for manufacturers
that is non-adhesive. The suggested use of Rev7™ is a maximum
of 15% of the total gum weight (Patent WO/2006/016179), result-
ing in consumption of up to 1.04 g per day. As an extra precaution
this level was doubled to 2 g for calculating safe concentrations of
metals and monomers.
Polymers with a molecular weight >1000 Daltons are not ex-
pected to be toxicologically active, because they are not expected
to cross the gastrointestinal epithelium (Scientiﬁc Committee on
Food, 2001). Given that Rev7™ has an average molecular weight
of 25,000 Daltons, no toxicological effects are expected to occur
when Rev7™ is ingested. However, possible contamination with
monomers, solvents and additives during manufacturing are of po-
tential concern, and thus studies were conducted to test for their
presence in Rev7™. In support of a thorough toxicological safety
assessment, the potential for the test article to produce genotoxic,
mutagenic, or other toxicological responses was also investigated.
4.1. Heavy metals
A lithium catalyst is used in the manufacturing of polyisoprene,
a precursor of the Rev7™ raw material PIP-g-MA, and is later
washed away with water. High doses of lithium are toxic to hu-
Table 2
Selected dataa from the REV7™ 28-day repeated dose oral toxicity study in Sprague Dawley rats.
Parameter Group number (ppm) males Group Number (ppm) females
1 (0) 2 (30,000) 3 (50,000) 4 (80,000) 1 (0) 2 (30,000) 3 (50,000) 4 (80,000)
Mean body weight (g) Day 0 228.4 ± 4.22 228.5 ± 5.50 228.1 ± 4.43 228.5 ± 5.56 185.8 ± 6.03 186.3 ± 6.48 185.8 ± 5.61 185.8 ± 6.21
Day 28 350.6 ± 20.59 337.9 ± 22.96 349.8 ± 23.64 342.1 ± 16.06 232.5 ± 10.51 222.7 ± 14.59 224.8 ± 12.91 227.2 ± 11.33
Mean daily weight gain (g) Days 0–28 4.4 ± 0.69 3.9 ± 0.75 4.4 ± 0.77 4.1 ± 0.46 1.7 ± 0.28 1.3 ± 0.46 1.4 ± 0.48 1.5 ± 0.38
Days 0–7 6.5 ± 0.91 5.6 ± 1.05 6.4 ± 1.01 6.1 ± 0.75 2.5 ± 0.83 2.9 ± 1.11 2.2 ± 1.21 2.4 ± 0.85
Days 7–14 5.3 ± 0.97 4.8 ± 1.20 5.3 ± 1.05 5.1 ± 0.51 2.2 ± 1.56 0.4** ± 1.22 1.6 ± 1.01 1.1 ± 1.03
Days 14–21 3.3 ± 0.77 2.6 ± 0.62 3.0 ± 0.82 2.7 ± 0.48 0.5 ± 0.88 0.7 ± 1.07 1.3 ± 1.78 1.0 ± 0.79
Days 21–28 2.4 ± 0.96 2.6 ± 0.58 2.7 ± 0.68 2.4 ± 0.86 1.5 ± 0.68 1.2 ± 1.16 0.6 ± 0.64 1.5 ± 1.05
Mean daily food intake (g) Days 0–28 23.6 ± 1.26 23.1 ± 1.57 24.7 ± 1.84 25.3 ± 1.33 16.5 ± 0.97 16.3 ± 0.69 17.5 ± 1.38 17.8 ± 0.77
Days 0–7 23.6 ± 0.83 23.4 ± 1.08 24.5 ± 1.5 25.1* ± 1.10 17.2 ± 0.84 18.2* ± 0.80 18.2 ± 1.10 18.8** ± 0.80
Days 7–14 24.1 ± 1.38 23.8 ± 1.63 25.7 ± 1.86 25.9* ± 1.27 16.8 ± 1.71 15.8 ± 1.47 17.3 ± 2.16 17.1 ± 1.60
Days 14–21 23.5 ± 1.37 23.0 ± 1.70 24.6 ± 2.15 25.1 ± 1.61 16.1 ± 1.37 15.6 ± 1.53 17.5 ± 1.93 17.2 ± 1.26
Days 21–28 23.3 ± 1.65 22.3 ± 2.22 24.0 ± 2.15 25.0 ± 1.89 15.9 ± 1.31 15.5 ± 0.88 17.0 ± 1.78 18.1** ± 0.84
Mean daily food efﬁciencyb Days 0–28 0.18 ± 0.02 0.17 ± 0.02 0.17 ± 0.02 0.16 ± 0.01 0.1 ± 0.01 0.08 ± 0.03 0.08 ± 0.02 0.08 ± 0.02
Days 0–7 0.27 ± 0.03 0.24* ± 0.04 0.26 ± 0.03 0.24 ± 0.02 0.15 ± 0.05 0.16 ± 0.06 0.12 ± 0.06 0.13 ± 0.04
Days 7–14 0.22 ± 0.03 0.20 ± 0.04 0.21 ± ± 0.03 0.2 ± 0.02 0.12 ± 0.09 0.02** ± 0.08 0.09 ± 0.05 0.06 ± 0.06
Days 14–21 0.14 ± 0.03 0.11* ± 0.02 0.12 ± 0.03 0.11* ± 0.02 0.03 ± 0.06 0.04 ± 0.07 0.07 ± 0.10 0.06 ± 0.05
Days 21–28 0.10 ± 0.04 0.12 ± 0.02 0.11 ± 0.02 0.10 ± 0.03 0.09 ± 0.04 0.08 ± 0.08 0.04 ± 0.04 0.08 ± 0.06
Hematology Hemaglobin (g/dL) 16.5 ± 0.4 16.2 ± 0.5 16.2 ± 0.5 16.3 ± 0.6 15.7 ± 0.7 15.9 ± 0.6 15.7 ± 0.4 15.8 ± 0.5
Hematocrit (%) 48.6 ± 1.4 47.8 ± 1.5 47.7 ± 1.6 48.0 ± 1.7 45.7 ± 2.0 45.7 ± 1.6 45.2 ± 1.3 45.4 ± 1.3
MCV (fL) 54.9 ± 1.2 54.4 ± 1.5 53.5 ± 1.5 53.4 ± 2.3 54.1 ± 1.1 52.6* ± 1.0 53.3 ± 0.8 53.6 ± 1.5
Absolute Basophils (103/lL) 0.04 ± 0.01 0.03 ± 0.02 0.04 ± 0.02 0.04 ± 0.01 0.02 ± 0.01 0.01* ± 0.01 0.01* ± 0.01 0.02 ± 0.01
Chemistry BUN (mg/dL) 20 ± 2 18 ± 3 21 ± 3 20 ± 3 19 ± 3 21 ± 3 20 ± 3 23* ± 3
Creatinine (mg/dL) 0.28 ± 0.03 0.27 ± ± 0.03 0.31 ± 0.03 0.30 ± 0.04 0.33 ± 0.03 0.34 ± 0.04 0.34 ± 0.04 0.35 ± 0.03
AST (U/L) 96 ± 9 91 ± 15 101 ± 29 98 ± 12 92 ± 13 91 ± 11 96 ± 9 92 ± 12
ALT (U/L) 41 ± 5 46 ± 9 49 ± 22 49 ± 6 37 ± 4 34 ± 4 35 ± 3 38 ± 7
Total protein (g/dL) 6.4 ± 0.3 6.5 ± 0.3 6.6 ± 0.2 6.7* ± 0.3 6.8 ± 0.2 6.6 ± 0.4 6.5 ± 0.2 6.5 ± 0.2
Albumin (g/dL) 3.3 ± 0.2 3.4 ± 0.1 3.4 ± 0.1 3.5 ± 0.1 3.6 ± 0.2 3.6 ± 0.3 3.5 ± 0.2 3.6 ± 0.2
Globulin (g/dL) 3.1 ± 0.2 3.1 ± 0.2 3.1 ± 0.2 3.2 ± 0.2 3.1 ± 0.1 3.0 ± 0.3 3.0 ± 0.3 2.9 ± 0.2
Calcium (g/dL) 11.2 ± 0.4 11.3 ± 0.4 11.3 ± 0.3 11.3 ± 0.5 11.2 ± 0.3 11.1 ± 0.5 10.8* ± 0.5 10.8* ± 0.2
Phosphorus (mg/dL) 8.7 ± 0.6 8.7 ± 0.7 8.9 ± 0.7 8.2 ± 0.8 7.6 ± 0.8 7.2 ± 0.9 7.1 ± 0.8 7.2 ± 1.0
Mean organ weights (g) Thymus 0.489 ± 0.122 0.408 ± 0.103 0.460 ± 0.093 0.431 ± 0.044 0.325 ± 0.037 0.318 ± 0.046 0.327 ± 0.034 0.317 ± 0.060
Adrenals (paired) 0.067 ± 0.009 0.073 ± 0.015 0.070 ± 0.011 0.078 ± 0.021 0.083 ± 0.009 0.082 ± 0.009 0.083 ± 0.009 0.081 ± 0.010
Heart 1.18 ± 0.09 1.14 ± 0.13 1.16 ± 0.10 1.20 ± 0.23 0.81 ± 0.06 0.75 ± 0.07 0.78 ± 0.08 0.84 ± 0.22
Spleen 0.75 ± 0.12 0.71 ± 0.11 0.73 ± 0.12 0.79 ± 0.14 0.64 ± 0.06 0.56 ± 0.08 0.60 ± 0.12 0.64 ± 0.06
Liver 10.09 ± 0.97 9.76 ± 1.02 9.84 ± 1.02 9.39 ± 0.78 6.27 ± 0.29 6.05 ± 0.32 5.81* ± 0.43 5.99 ± 0.52
Testes or Ovaries (paired) 3.78 ± 0.13 3.47 ± 0.72 3.35*±0.66 3.70 ± 0.14 0.135 ± 0.013 0.136 ± 0.031 0.137 ± 0.022 0.143 ± 0.026
Kidneys (paired) 2.51 ± 0.27 2.68 ± 0.43 2.59 ± 0.34 2.60 ± 0.27 1.65 ± 0.13 1.59 ± 0.09 1.56 ± 0.13 1.57 ± 0.12
Epididymides or Uterus/Fallopian tubes (paired) 1.267 ± 0.082 1.221 ± 0.167 1.180 ± 0.156 1.263 ± 0.110 0.65 ± 0.41 0.63 ± 0.30 0.46 ± 0.14 0.54 ± 0.10
Brain 1.92 ± 0.14 1.91 ± 0.07 1.94 ± 0.08 1.81 ± 0.16 1.83 ± 0.09 1.85 ± 0.07 1.79 ± 0.09 1.84 ± 0.07
Mean organ to brain weight ratio Thymus 0.254 ± 0.057 0.215 ± 0.056 0.237 ± 0.043 0.240 ± 0.035 0.178 ± 0.018 0.172 ± 0.025 0.183 ± 0.023 0.173 ± 0.033
Adrenals (paired) 0.035 ± 0.006 0.038 ± 0.008 0.036 ± 0.006 0.043 ± 0.013 0.046 ± 0.003 0.044 ± 0.005 0.046 ± 0.004 0.044 ± 0.005
Heart 0.62 ± 0.06 0.60 ± 0.07 0.60 ± 0.04 0.67 ± 0.13 0.44 ± 0.03 0.41 ± 0.03 0.44 ± 0.04 0.46 ± 0.10
Spleen 0.39 ± 0.05 0.37 ± 0.05 0.34 ± 0.13 0.44 ± 0.06 0.35 ± 0.04 0.30* ± 0.04 0.33 ± 0.06 0.35 ± 0.03
Liver 5.28 ± 0.48 5.12 ± 0.57 5.08 ± 0.49 5.23 ± 0.67 3.43 ± 0.17 3.28 ± 0.18 3.25 ± 0.23 3.27 ± 0.33
Testes or Ovaries (paired) 1.98 ± 0.16 1.82 ± 0.37 1.73 ± 0.34 2.06 ± 0.19 0.074 ± 0.007 0.074 ± 0.017 0.076 ± 0.011 0.078 ± 0.013
Kidneys (paired) 1.31 ± 0.16 1.41 ± 0.22 1.33 ± 0.14 1.46 ± 0.28 0.90 ± 0.06 0.86 ± 0.04 0.87 ± 0.06 0.86 ± 0.07
Epididymides or Uterus/Fallopian tubes (paired) 0.664 ± 0.065 0.639 ± 0.084 0.609 ± 0.070 0.706 ± 0.112 0.35 ± 0.21 0.34 ± 0.17 0.26 ± 0.08 0.30 ± 0.06
* p < 0.05.
** p < 0.01.
a Data that is not shown was not statistically different between groups.
b Food Efﬁciency = mean daily body weight gain/mean daily food consumption.
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1000 lg/day for a 70 kg adult has been proposed (Schrauzer, 2002).
Heavy metal contamination from environmental sources is also
possible during manufacturing.
Rev7™ had lithium and heavy metal concentrations below the
detection limit, or at levels calculated to be well below maximum
safe exposure limits for humans at double the expected Rev7™
consumption level (2 g per day) (WHO, 2004) (California Ofﬁce of
Environmental Health Hazard Assessment, 2009) (McGufﬁn, 2008).
4.2. Monomers and solvent residue
The isoprene monomer is widely used in the production of poly-
mers, and while literature available in the public domain is lacking
regarding the safety of human ingestion of the substance, repeated
oral toxicology studies in animals have shown toxic effects (SIDS
Initial Assessment Meeting, 2005).
Ethylene oxide is a monomer used in the manufacturing of PEG
and MPEG; substances that are also regarded as safe for consump-
tion. MPEGs have a range of uses in the cosmetic and pharmaceu-
tical industries (Dow Chemical Company, 2006; Clariant GmbH,
2003). The Scientiﬁc Committee on Foods states allowable average
limits of 1–5 ppm ethylene oxide in certain food additives (Scien-
tiﬁc Committee on Food, 2002). Because isoprene and ethylene
oxide have boiling points of 34 C and 10.7 C, respectively, and
the production of Rev7™ takes place at temperature of over
120 C, it is highly unlikely that any residue of the two remain in
Rev7™; which was conﬁrmed during analytical testing.
Hexane and methanol are used in the production of the Rev7™
synthetic starting material, PIP-g-MA. Hexane is permitted by the
FDA as a secondary direct food additive permitted for human con-
sumption in spice oleoresins at a level of up to 25 ppm (FDA 21 CFR
173.270). The Food Additives and Contaminants Committee rec-
ommends a maximum methanol concentration of 8 ppm in food
(Bozza-Marrubini et al., 1988). Neither hexane, methanol, isoprene
nor ethylene oxide were detected in the Rev7™ batches tested, at
detection levels of 0.5, 1, 0.05, and 1 ppm, respectively.
Lastly, maleic anhydride is a compound used in copolymeriza-
tion reactions (National Center for Biotechnology Information,
2009). The EPA integrated risk information system (IRIS) lists a ref-
erence dose (a daily exposure estimate that is likely to be without
appreciable risk) for maleic anhydride of 0.1 mg/kg/day (EPA, 1988,
2008). This is equivalent to 7 mg/day for an average 70 kg person.
Maleic anhydride was detected in Rev7™ at a maximum level of
0.08%; if consumption of Rev7™ were estimated at 2 g per day
(twice the expected consumption level), the consumption expo-
sure to maleic anhydride would be 1.6 mg – well below the EPA’s
reference dose.
4.3. Bht
Butylated hydroxytoluene (BHT) is an FDA permitted additive
for chewing gum and is added as a stabilizer to the ﬁnal formula-
tion. The maximum FDA allowable concentration of BHT in chew-
ing gum is 0.1% (1000 ppm) (FDA 21 CFR 172.615). The average
level of BHT in Rev7™ tested in this safety assessment was
229 ppm, which is well within the presently acceptable FDA limits.
4.4. Allergic potential
The murine local lymph node assay was performed due to the
use of MPEG, isoprene and PIP-g-MA in the manufacturing process
of REV7™. There have been several reports in the literature of aller-
gic responses associated with the use of PEG and MPEG products
(Belsey et al., 2008). Both contact dermatitis and immediate hyper-
sensitivity reactions to oral PEG derivatives have been described(Anton Girones et al., 2008; Schuman and Balsam, 1991; Le Coz
and Heid, 2001; Taibjee et al., 2003, Stenveld et al., 1994), although
these reports are extremely rare considering the extensive use of
PEG products by the cosmetic, food and pharmaceutical industries.
Published safety assessments of PEG derivatives have determined
that they are safe for use in cosmetics (Anon, 2006, 2004; Lanigan
and Yamarik, 2001), with the stipulation that they should not be
used on skin lesions. When ingested, absorption in the digestive
tract is inversely proportional to the molecular weight of the PEG
compound, with larger molecular weight compounds resulting in
little to no absorption. The physical properties of M-type polygly-
cols are comparable to pure polyethylene glycols. MPEG used in
the manufacturing of Rev7™ has an average molecular weight of
2000–5000 Daltons.
Natural latex, containing polyisoprene and protein, is isolated
from the Hevea brasiliensis tree in South East Asia and has many
consumer uses (Toraason et al., 2000). Latex contains proteins that
frequently cause serious allergic reactions in sensitive humans.
These reactions are most commonly observed in the form of con-
tact dermatitis through type IV delayed hypersensitivity reactions
(Toraason et al., 2000; Taylor and Erkek, 2004).
Rev7™ (and more speciﬁcally its precursor PIP-g-MA) is manu-
factured using synthetic isoprene rather than latex or natural iso-
prene. Because synthetic isoprene does not contain the residual
proteins found in natural isoprene, it is unlikely to cause allergic
responses. In fact, gloves made with synthetic polyisoprene are
recommended for individuals with latex allergy (Taylor and Erkek,
2004).
In 2006, the sensitization potential of PIP-based polymers was
described in an unpublished study by Kuraray Co., Ltd. (Personal
Communication, Kuraray Co., Ltd.). The report was based upon
the results from a murine local lymph node assay, which identiﬁes
substances with the potential to cause delayed skin sensitization
reactions by indirectly determining lymphocyte proliferation at
the lymph node sites (National Toxicology Program, 1999). The
investigators found that PIP (LIR-30) was not a skin sensitizer,
whereas PIP-g-MA (LIR-403) was a skin sensitizer with a SI value
of 3. A score of greater than or equal to 3 indicates the potential
of a substance to be a skin sensitizer. It has been suggested that
the skin-sensitizing properties of PIP-g-MA are due to the maleic
anhydride grafts reacting with proteins found in the skin (Personal
Communication, Kuraray Co., Ltd.).
Because PIP-g-MA is a reactant in the manufacturing of REV7™,
the skin sensitization potential of Rev7™ was investigated. Rev7™
was not found to possess skin-sensitizing properties under these
conditions. This is likely due to the fact that the maleic anhydride
moiety reacts with MPEG during the manufacturing process.4.5. Toxicology studies
The safety of Rev7™ was assessed in several toxicological stud-
ies. While no mutagenic effects were noted from the results of the
AMES assay, the test article extract at the highest concentration
tested was found to be mutagenic in the mouse lymphoma TK
mutation assay under one of the conditions tested. In this assay,
exposure to Rev7™ in the absence of a metabolic activation system
resulted in growth inhibition of cells and increased revertant num-
bers at the highest concentration. Because of these in vitro results,
it was necessary to follow-up with a second mutagenicity assay
performed in vivo (the micronucleus test performed in mice). In
this second assay, Rev7™ was negative for any genotoxic effects.
The weight of this evidence indicates that Rev7™ does not pose
genotoxic concern. Dietary administration of Rev7™ at dose levels
of 30,000, 50,000 and 80,000 ppm for 28 days produced no evi-
dence of toxicity in male or female rats.
838 T.M. Farber et al. / Food and Chemical Toxicology 48 (2010) 831–8385. Summary and conclusion
Analytical testing for heavy metals, monomers, solvents, and
additives present in the tested batches of Rev7™ were all within
safe limits. Rev7™ was considered non-mutagenic in the AMES
and mouse chromosomal aberration assays; although mutagenic-
ity was observed at the highest dose tested in the mouse lym-
phoma TK assay under conditions of non-metabolic activation
and 24 h (long) exposure time. Rev7™was not found to be a poten-
tial skin sensitizer in the mouse local lymph node assay. The 28-
day repeated oral toxicity test resulted in no toxic effects; hence
the NOAEL (No Observed Adverse Effect Level) for Rev7™ was
determined to be 80,000 ppm of the diet for male and female rats
– equivalent to 6.879 g/kg/day for males, and 6.844 g/kg/day for
females.
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